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Abstract: Prevalence of infections by Helicobacter pylori, a pathogen involved in a 
number of gastrointestinal diseases, remains high in developing countries. Management of 
infections by eradication is not always an option. Lactobacillus reuteri (L. reuteri) 
DSMZ17648 (Pylopass™/Lonza) specifically co-aggregates H. pylori in vitro and was 
shown to reduce 
13
C urea breath test in vivo. In this pilot study, we tried to replicate 
previous findings in an independent sample and to evaluate effects of spray-drying vs. 
freeze-drying of cultures. A single-blinded, placebo-controlled study was done in  
22 H. pylori positive, asymptomatic adults. H. pylori levels were determined by  
13
C-urea-breath method after 14 days of supplementation, as well as after 6, 12, and  
24 weeks follow-up. In the test group, but not in the placebo group, a significant reduction 
of H. pylori was observed. For the first time, spray-dried cells of L. reuteri DSMZ17648 
have been used in a human study and results are in line with the first study results, 
supplementing with freeze-dried material. This is of special interest as spray-drying results 
in dead cell material, meaning that the effect of L. reuteri must be independent of its 
probiotic activity. These results confirm the potential of Pylopass™ as a novel way to 
reduce the load of H. pylori. 
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1. Introduction 
H. pylori is a gram negative, spiral-shaped human pathogen infecting an estimated 50% of the 
global population. There is great disparity in the prevalence of infection between developed and 
developing nations. The average prevalence in developed countries in those <40 years old is 20% 
whereas developing countries have a prevalence rate of 80%–90% [1]. This makes measures for 
control most relevant for regions, such as South and Far East Asia, Africa and Latin America. 
H. pylori is able to survive the acidic environment of the stomach and to adhere to the gastric 
mucosa, colonizing the mucosal lining of the stomach. An estimated 10
4–107 H. pylori colony forming 
units (CFU) per g of gastric mucus can be found in infected persons [2]. 
H. pylori is associated with a number of gastrointestinal diseases, such as peptic ulcer disease and 
gastric cancer [3]. Infection by H. pylori may lead to an inflammatory response, increased secretion of 
gastric acid, and type-B gastritis. There is evidence of a relationship between the level of gastric 
colonization by H. pylori and the probability of symptoms/onset of disease [4]. In the National Health 
and Nutrition Examination Survey III, H pylori was not associated with all-cause mortality. H pylori 
was strongly positively related to gastric cancer mortality. There was an inverse association of H pylori 
status with stroke mortality, pointing to possible protective effects [5]. 
The management of H. pylori infections is still a matter of discussion. The fourth edition of the 
Maastricht Consensus Report provides diagnostic guidelines and therapeutic strategies for H. pylori 
infection [6]. In dyspeptic patients, a test-and-treat strategy is proposed. Therapeutic options for  
H. pylori-infection aiming at complete eradication include various combinations of proton pump 
inhibitors combined with two to three antibiotics. This complex approach has inherently high risks of 
side effects and non-compliance. Furthermore, this push towards eradication has been challenged for 
developing countries like India where high prevalence, increasing resistance, diversity of strains, 
together with high risk of recurring infections would make test-and-treat potentially more harmful than 
beneficial at the community level [7]. The Maastricht Consensus Report also does not state that 
eradication treatment is indicated for asymptomatic individuals with H. pylori. 
Therefore, there remains a therapeutic gap for persons infected by H. pylori, but still without 
clinically relevant pathology [8]. 
The efficacy of using probiotics in the prevention and treatment of various gastrointestinal diseases 
has been summarized in a recent review, confirming the potential for beneficial health effects [9]. 
These benefits could apply to the treatment of infections by H. pylori as well. Of special interest in that 
context is the increasing evidence that not just living probiotics but also dead cells or even cell 
fractions seem to be sufficient to modify biological responses. Adams reports several cases of heat 
killed probiotic strains exerting positive influences, including reduction of cholesterol, attenuation of 
allergic response and pain modulation. [10]. 
The aim of the development of a specific Lactobacillus is to close the therapeutic gap in 
asymptomatic infection and to provide new preventive options to patients by lowering the risk for 
gastric ulcer or carcinoma, thereby avoiding severe adverse effects and treatment expenses. In a 
previous placebo-controlled proof-of-concept in vivo study we tested Lactobacillus reuteri strain 
DSMZ17648 (Pylopass™/Lonza) [11]. This specific strain was found by screening hundreds of 
Lactobacilli strains of a large culture collection (Organobalance GmbH, Berlin, Germany). This strain 
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was tested for antibiotic resistance and no resistance was identified. A significant reduction in 
13
C-urea 
breath test (UBT) indicated reduction of bacteria load after active treatment with freeze-dried cells, 
while no effects were found for placebo control in asymptomatic humans after the two-week 
supplementation period. Lactobacillus reuteri is found in both human breast milk as well as the 
microflora of the gastrointestinal tract. Strains of L. reuteri have been shown to confer health benefits 
in a variety of cases, including infant colic, gastrointestinal disorders in children and feeding 
intolerance in pre-term infants [12]. Inhibitory effects of L. reuteri (ATCC 55730) on H. pylori have 
been reported as well [13]. 
The primary objective of this study was to replicate in an independent sample previous findings of 
the impact of two weeks of Pylopass™ supplementation on H. pylori load as measured by 13C-UBT. 
The secondary objective of this study was to evaluate whether a change in the manufacturing process 
of L. reuteri DSMZ17648 from freeze-drying to spray-drying impacts the effectiveness of the 
supplement. Spray-drying does have obvious advantages over freeze-drying not only with regard to 
production cost but also with regard to storage stability of the product. 
2. Experimental Section 
The study was approved by the local ethics advisory committee (Charité, Berlin, Germany). The 
study was conducted according to the Declaration of Helsinki and is registered at ISRCTN 
(International Standard Randomised Controlled Trial Number ISRCTN70607306). 
2.1. Study Population 
Sample size was estimated in a power calculation as 20 subjects; allowing for potential drop-outs 
this number was increased by 10%. The study population included 22 H. pylori positive subjects  
(5 male, 17 female, mean age 47 ± 16). Subjects were included if they had reached the age of 18, had 
documented informed consent, a positive finding in the antibody-based screening test (Diagnostik 
Nord, Schwerin, Germany), and a positive H. pylori finding in the 
13
C urea breath test (Helicobacter 
Test INFAI
®
, (INFAI GmbH, Köln, Germany), δ ≥ 12‰). Exclusion criteria were intake of any 
medication interfering with the action of the lactobacilli, previous surgical procedures affecting 
stomach or small intestine with potential interference with the study, e.g., gastrectomy or gastric 
bypass, diabetes type 1 or 2, familiar lipid metabolism diseases, liver disease, kidney insufficiency, 
autoimmune disease, organ transplantation, weight changes >3 kg over the last three months, 
eradication therapy, lactose intolerance, oral intake of antibiotics <3 months ago, intake of PPIs or  
H2 antagonists, pregnancy or lactation, alcohol or drug abuse, psychiatric diseases or participation at 
other clinical trials at the same time. None of the participants met the criteria set forth by the 
Maastricht Guidelines for eradication therapy [6]. 
2.2. Study Supplements 
The test product (active ingredient) consisted of spray-dried dead cells of the Lactobacillus reuteri 
strain DSMZ17648, prepared as solid tablets (Quimifarma S.L., Yuncos (Toledo), Spain) for oral 
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application. Each tablet contained 5 × 10
9
 cells and the daily dosage of 4 tablets translates into 2 × 10
10
 
cells. Supplement and placebo tablets were identical in weight (250 mg), size, color and flavor. 
2.3. Study Protocol 
Supplement and placebo were given in a single-blinded, crossover design. All tests were done at the 
clinical research center of the Charité in Berlin-Buch. Following a first urea breath test, there were  
14 days of placebo-run in. After a second breath test, the supplement was given for 14 days, followed 
by a third breath test. To test mid-term effects, follow-up measures were taken at 6, 12, and 24 weeks 
after the end of supplementation. 
Subjects were instructed to take two tablets after breakfast as well as after their evening meal. 
During the supplementation period participants were instructed not to initiate any lifestyle or  
dietary changes. 
Subjects were asked to answer a study-specific questionnaire to document well-being, any potential 
side effects, smoking, alcohol use, nutrition and medication. 
To test for physiological changes relevant in terms of safety, fasting blood samples were taken 
before and after the supplementation period to determine levels of cholesterol, triglycerides, glucose, 
gamma-GT, GPT (ALAT), GOT (ASAT), creatinine, erythrocytes, hematocrit, hemoglobin, MCV 
(mean corpuscular volume), MCHC (mean corpuscular hemoglobin concentration), leukocytes, 
thrombocytes, total bilirubin, uric acid, urea, CRP (C-reactive protein), and the coagulation parameters 
INR (international normalized ratio) and PTT (partial thromboplastin time). 
2.4. Outcome Measurements 
Detection of H. pylori infection in the screening phase was performed with an antibody-based quick 
test (Diagnostik Nord, Schwerin, Germany). Quantification of colonization for confirmation of 
eligibility and to verify effects of DSMZ17648 was accomplished by a breath test, as this diagnostic 
approach is best suited to detection of intraindividual changes [14]. Helicobacter Test INFAI
®
 (INFAI 
GmbH, Köln, Germany) is a breath test for direct non-invasive semi-quantitative detection of the 
bacterium H. pylori [15]. The test is based on the urease activity of H. pylori. Patients ingest 75 mg of 
the 
13
C urea isotope. In the presence of H. pylori, 
13
C urea is hydrolyzed to ammonium and  
13
C-labelled carbon dioxide, which is detectable by mass spectroscopy in the breath. As there is a small 
amount of naturally occurring 
13
C present in the exhalation air even in the absence of urease activity, 
breath samples are taken before and 30 min after the ingestion of 
13
C urea. An infection with H. pylori 
is regarded as proven if the difference in 
13
C/
12
C of 0-min-value and 30-min-value exceeds 4‰.  
If there is no difference, the test is negative, indicating no infection with H. pylori. There is a 
quantitative relation between urease activity and amount of 
13
C in breath in fasted subjects, that 
indirectly relates to the level of colonization by H. pylori, making it well suited to detect reduction or 
eradication of the bacteria [15,16]. In this study, subjects were included if their breath test value was 
>12‰, indicating a moderately high colonization level of H. pylori. Specificity (98.5%) and sensitivity 
(97.9%) of Helicobacter Test INFAI
®
 are comparable to traditional invasive diagnostic methods 
(endoscopy or biopsy) [17]. 
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2.5. Statistics 
All data were entered into a dedicated trial database. Statistical analysis was conducted using  
R (Version 3.0.1, R Foundation for Statistical Computing, Vienna, Austria) [18]. We computed 
differences in 
13
C Urea Breath Test (UBT) values against initial measurements: ∆active = 13C UBT 
active − 13C UBT initial, ∆placebo = 13C UBT placebo − 13C UBT initial. Additionally, the absolute 
test values between the various study time-points were compared: 
13
C UBT initial, 
13
C UBT active 
(after 14 days active treatment), 
13
C UBT placebo (after 14 days placebo treatment). 
Due to the selection criteria (
13
C UBT > 12‰ at baseline), deviation from normal distribution was 
assumed and differences were tested by Skillings-Mack test for multiple repeated measurements.  
If significant, pairwise Wilcoxon tests were applied to distinguish placebo and treatment effects.  
An error level of 5% was set as threshold for significance. Results are reported as median and  
1st/3rd quartile. 
3. Results 
3.1. Reduction of H. pylori 
Screening included 364 subjects, of which 22 subjects had a positive quick test and a 
13
C UBT 
result above the threshold of 12‰, indicating at least moderately high colonization by H. pylori. 
Details of the screening population are given in Table 1. 
Table 1. Characteristics of screening population. 
 Total Included Excluded 
n 364 22 342 
Age (years ± SD) 47 ± 20 47 ± 16 47 ± 20 
Sex (male/female) 108/256 5/17 103/239 
Overall, 22 subjects started supplementation, with no drop-outs during the trial phase. There was 
large interindividual variability of quantitative measures of colonization at baseline as well as during 
treatment, together with substantial intraindividual variability between measurements. Main analysis of 
H. pylori reduction by DSMZ17648 was based on median values of absolute values of 
13
C UBT at 
baseline measurement, after placebo and after active treatment, Figure 1. 
Results for the 
13
C UBT are reported in Table 2, including absolute values during trial phases as 
well as absolute and relative differences between baseline and supplementation phases. Only the 
difference between 
13
C UBT at baseline (median = 20) and after DSMZ17648 supplementation 
(median = 16) reached statistical significance (p = 0.011), while baseline and placebo (median = 18) 
did not differ (p = 0.237). There was a statistical trend for DSMZ17648 values to be lower than 
placebo (p = 0.084). 
We calculated individual absolute differences as well as change scores (change in % of baseline). 
For DSMZ17648, both absolute difference and change score are significant (p = 0.018 and 0.013, 
respectively), indicating a reduction of H. pylori (Figure 2). For placebo, neither absolute nor relative 
changes are significantly differing from 0, suggesting random variation rather than a systematic reduction. 
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Figure 1. Absolute 
13
C-urea breath test (UBT) values before and after supplementation 
with placebo or Pylopass™. 
 
Table 2. Breath test findings in study population, results are reported as median  
(25./75. percentile). 
 Baseline Placebo Pylopass™ 
Absolute values (‰) 20 (16/26) 18 (15/28) 16 (8/30) *,+ 
Absolute change vs. baseline (‰)  0 (−6/3) −5 (−11/0) + 
Relative change vs. baseline (%)  −3 (−27/20) −16 (−47/1) + 
* p < 0.05 vs. baseline; + p < 0.1 vs. placebo. 
Figure 2. Percentage of change of 13C UBT after placebo and Pylopass™. 
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We tested prolonged effects by repeating the 
13
C UBT at 6, 12, and 24 weeks after the end of 
supplementation. Results are shown in Figure 3, the significant lowering found immediately after 
supplementation was still detectable after 24 weeks. 
Figure 3. Absolute 
13
C UBT values before and after supplementation with Pylopass™ as 
well during follow-up. 
 
After supplementation with L. reuteri DSMZ17648, not all subjects showed a reduction in H. pylori 
colonization. Responses show some variability, studying potential predictors for response may define a 
subgroup of patients most likely to benefit. This will require substantially larger study groups in the future. 
3.2. Safety Parameters 
No side effects were reported during 14 days of either placebo or DSMZ17648 supplementation. 
There were no statistically significant alterations in a complete blood cell profile or in circulating 
metabolic enzymes with markers of liver and renal function measured as safety parameters before and 
after the supplementation period. During the course of the study no changes in lifestyle (physical 
activity, diet), or in general health were detected as indicated by the questionnaire. 
3.3. Effects of Spray-Drying 
A secondary objective of this study was to evaluate a change in the preparation of the test culture, 
i.e., a shift from freeze-drying cells to spray-drying. We compared the absolute change in 
13
C UBT 
between a previous study with freeze-dried DSMZ17648 [11] and our current results (Figure 4). The 
results clearly indicate that the process of spray-drying is equally effective. Both types of preparation 
of non-viable lactobacillus cells show significant reduction in H. pylori. 
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Figure 4. Comparison of freeze-dried and spray-dried L. reuteri supplement in terms of 
change of 13C UBT after placebo and Pylopass™. 
 
4. Discussion 
Despite the causal link between H. pylori infections and gastrointestinal pathology, only a minority 
of infected subjects actually develops disease [19]. For those with acute symptoms, eradication in a 
test-and treat approach is usually recommended as the standard procedure. Yet on the population level, 
this may neither be necessary nor achievable, especially in regions with high prevalence and poorly 
developed health systems. Given the interaction between infections with H. pylori and mental stress in 
gastrointestinal diseases [20], short-term reduction may be another viable option during stressful life 
events, such as, e.g., exams, excessive work load, or other emotional distress. 
This in vivo study shows a significant decrease of H. pylori stomach colonization after 
Lactobacillus reuteri DSMZ17648 supplementation in asymptomatic subjects with detectable  
H. pylori infection. It replicates our previous findings in an independent general population sample 
free of overt gastrointestinal diseases or alarm symptoms. Primary objective of this study was the 
reduction of H. pylori as measured by 
13
C urease breath test (Helicobacter Test INFAI
®
) after a 14 day 
supplementation period of L. reuteri DSMZ17648 (Pylopass™) at a daily dose of 2 × 1010 non-viable 
spray-dried cells. 
This finding gives a strong foundation for the assumption that consumption of DSMZ17648 might 
exert a preventive effect of secondary diseases and related symptoms due to H. pylori infection. It is of 
special relevance that the preventive effect is carried over well after the supplementation itself, at least 
for the six month period covered by our follow-up. 
Probiotics are defined as live microorganisms which when administered in adequate amounts confer 
a health benefit to the host (FAO/WHO) [21]. In the context of H. pylori infection, probiotics are 
administered along with eradication therapy to ease side-effects. Medeiros et al. [22] studied the 
impact of Lactobacillus acidopholus on side effects associated with a common triple regimen 
eradication therapy but found no measurable effect. However, there are some studies where probiotics 
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are used alone in the treatment of H. pylori, based on a broad range of cultures and outcomes. 
Francavilla et al. supplemented a different strain of Lactobacillus reuteri (ATCC 55730) for  
four weeks and found a significant reduction in H. pylori load [13]. As they had included patients 
showing some gastrointestinal symptoms, they could verify a reduction in symptom scores during 
treatment. A study applying L. casei for three weeks reported a non-significant suppressive effect [23]. 
Fourteen H. pylori-positive subjects receiving drinks with 10
8
 colony-forming units/mL L. casei thrice 
daily during meals for three weeks were compared to six untreated H. pylori-positive subjects as 
controls. Urease activity decreased in nine of the 14 (64%) subjects with L. casei supplementation and 
in two of the six (33%) controls (p = 0.22). A slight, but nonsignificant trend towards a suppressive 
effect of L. casei on H. pylori in vivo may exist. In vitro experiments showed that viable L. casei are 
required for H. pylori growth inhibition. 
Reduction of H. pylori with L. brevis administration has also been reported [24]. Twenty-two  
H. pylori-positive dyspeptic patients randomly (ratio 1:1) received high oral doses of lyophilisated  
L. brevis (CD2) or placebo nine times a day for three weeks. L. brevis (CD2) treatment did not 
eradicate H. pylori. However, a reduction in the UBT delta values occurred, suggesting a decrease in 
intragastric bacterial load. 
In the case of L. acidophilus (johnsonii) La1 the whey-based supernatant was found to induce a 
marked decrease in H. pylori breath test analyses, both in combination with Omeprazol and alone [25]. 
While these studies showed some promising results, further research is needed to determine the 
efficacy of such methodology in a general population. 
Potential mechanisms by which probiotics may influence H. pylori may include strengthening of the 
non-immunological barriers representing a first line of defense against pathogenic bacteria by 
producing antimicrobial substances, or stabilization of the gut mucosal barrier. Other mechanisms 
could be sequestration of H. pylori, competitive binding to adhesion receptors for H. pylori [26,27], 
binding to surface structures of H. pylori, thus preventing adhesion to the mucosa. Antimicrobial 
substances have been implicated in the inhibition of H. pylori by lactic acid bacteria. Short chain fatty 
acids (SCFAs, e.g., formic, acetic, propionic, butyric and lactic acid) have an important role in 
decreasing the pH, and are produced during the catabolism of carbohydrates. Such antimicrobial 
activity could either be due to a direct effect on H. pylori but also a secondary effect of the inhibition 
of its urease activity [28]. Current research suggested that living cells may not be mandatory for health 
effects, as dead cells, cell fractions, or supernatant may be as efficient in some cases. For the specific 
strain of L. reuteri studied in this project, supplementation of both freeze-dried and spray-dried cells 
has been shown to reduce H. pylori. The most plausible explanation is that structures on the cell 
surface of this selected strain are responsible for the therapeutic effect and were unaffected by the 
different drying processes. 
DSMZ17648 specifically co-aggregates H. pylori under in vitro conditions and in artificial gastric 
juice, without interfering with other bacteria of the commensal intestinal flora [29]. This specific 
binding may mask surface structures of H. pylori and interfere with Helicobacter motility. The 
aggregated pathogens presumably no longer adhere to the gastric mucosa and are cleared from the 
stomach. An additional mode of action may be competition for specific binding proteins [30]. 
The present study should be regarded as a pilot trial, as sample size was limited. Larger clinical 
studies should be conducted in the future to validate these results. Establishment of predictors for 
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response to DSMZ17648 as well as more precise estimation of effect size will require larger samples. 
Although most other human trials [22–25] have used the 13C urea breath test to study the effects of 
probiotics on H. pylori colonization, the outcome of 
13
C Urea Breath Test reflects H. pylori 
colonization density in a semi-quantitative way only, making intraindividual changes in test scores 
only a proxy for intervention effects. Deviation from fasting conditions may influence test outcomes  
as well [31]. 
5. Conclusions 
There are many potential applications of L. reuteri DSMZ17648. It may reduce H. pylori load in 
high prevalence populations or be used as short-term prophylaxis during high stress periods. L. reuteri 
DSMZ17648 could also be utilized for chronic, long-term prophylaxis. 
Providing access to probiotic cultures in the form of supplements and food products requires 
sophisticated supply chains which may not be available in regions with the highest need. Dead cells, 
such as the ones used in the present study, are more stable than true probiotics. Therefore, they can be 
applied in a wider range of delivery systems to populations which may lack proper storage. L. reuteri 
DSMZ17648 may also be useful in populations with high H. pylori prevalence where antibiotic 
therapy has low compliance for cost reasons. Compared to living probiotic cells, dead cells are 
advantageous in that storage and delivery is less demanding, shelf life is prolonged and production 
costs are reduced. Taken together, these characteristics could make the application of dead cells a 
realistic new approach to H. pylori control. 
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